Fc-optimized HuMab 5B1 (MabVax Therapeutic/Rockefeller University)

N/A

Report date: 2025/03/20 15:43:54

Base Information

Drug NameFc-optimized HuMab 5B1 (MabVax Therapeutic/Rockefeller University)
Drug Alias NameHuMab 5B1-FcFc optimization of HuMab 5B1 (MabVax Therapeutics/Rockefeller University)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMabvax Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesMabvax Therapeutics Holdings IncThe Rockefeller University
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A